| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Oragenics Inc.$0.59
+0.01 (+1.68%)
D 22Pipeline Score Overvalued Pharma · Clinical
Market Cap
2.69 M
EPS
-6.12
P/E Ratio
-
Value Trade
25.71 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
645.47 K
Operating CF
-2.20 M
Total Assets
7.49 M
Total Liabilities
1.31 M
Equity
6.18 M
D/E Ratio
12,345
3.83 %
Week
-14.09 %
1 Month
-11.82 %
3 Month
-36.49 %
6 Month
-99.95 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.11 M
Monthly Burn
734.00 K
Runway
6.4 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
11.31 K
52 Week Range
0.50 - 9.60
% held by Insiders
0.17 %
% held by Institutions
4.2 %
Enterprise Value
-3.36 M
Total Shares
4.33 M
Short %
23.47 %
Float Shares
3.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oragenics Inc.
423Total events
8Upcoming
68Tier-1 (high impact)
2007 – 2027Coverage
Upcoming catalysts 8
Event history 415
Q3 2026
◆Topline ReadoutONP-002Clinical Data
Phase IIa data readout
concussion (mild traumatic brain injury)source ↗
Q3 2026
●NDA SubmissionONP-002Regulatory Filing
FDA Accelerated Approval Filing (if eligible)
concussionsource ↗
Jun 29, 2026
▲Enrollment CompleteONP-002Trial
All three Australian Phase IIa trial sites active and enrolling
mTBI (concussion)source ↗
Jun 26, 2026
Jun 21, 2026
▲First Patient DosedONP-002Trial
Alfred Health enrolls first participant in Phase IIa trial
mTBI (concussion)source ↗
May 21, 2026
May 18, 2026
May 7, 2026
▲Partnership / LicenseCardioDialysisCorporate
Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI and neurodegenerative diseases
Traumatic Brain Injury (TBI) and other chronic neurodegenerative diseasessource ↗
May 7, 2026
◆Trial InitiationONP-002Trial
ONP-002 Phase IIa clinical trials ongoing for concussion and mTBI
concussion and mild traumatic brain injury (mTBI)source ↗
Drug Pipeline Intelligence
D22
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 21%
Micro Cap (rank 721 of 911)
Percentile RankOragenics Inc. faces pipeline headwinds (22/100), with $117M risk-adjusted pipeline value, led by Neurosteroid enantiomer in Mild Traumatic Brain Injury, Concussion (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurosteroid enantiomer Small molecule | Mild Traumatic Brain Injury, Concussion | Phase 2 | NCT06870240 | 14% | $117M | NOT YET_RECRUITING | 40 | AVERAGE | C (49) | Mar 31, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ONP-002 | concussions | Phase 2 | 2024-10-09 | strong safety profiles; strong cardiac safety margin; does not cause DNA damage; 4-fold increase in drug percentage per dose Read More | Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation Read More | |
ONP-002 | concussions | Phase 2 | 2024-10-09 | strong safety profiles; strong cardiac safety margin; does not cause DNA damage; 4-fold increase in drug percentage per dose Read More | Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation Read More | |
ONP-002 | concussions | Phase 2 | 2024-10-09 | strong safety profiles; strong cardiac safety margin; does not cause DNA damage; 4-fold increase in drug percentage per dose Read More | Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OGEN▲ +1.7%today
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Oragenics has successfully activated all three sites for its Phase IIa trial in Australia, with the first participant enrolled at Alfred Health. The company is also progressing its U.S. regulatory pathway for ONP-002, aimed at treating mTBI. No serious adverse events have been reported so far, and a Phase IIa data readout is expected in Q4 2026.
Read more →OGENOragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Oragenics, Inc. will present at Sidoti's Micro-Cap Virtual Investor Conference on May 20-21, 2026. The presentation will showcase the company's lead candidate, ONP-002, which is in Phase IIa trials for concussion treatment. Investors can register for the presentation and one-on-one meetings, emphasizing Oragenics' proactive investor engagement.
Read more →OGENORAGENICS PROVIDES INVESTOR UPDATE
Oragenics, Inc. has provided an investor update highlighting the active Phase IIa clinical trial of ONP-002 for concussion treatment in Australia. The company has successfully activated multiple trial sites and is progressing towards U.S. clinical trials with plans for an FDA Type C Meeting Request. Additionally, a Letter of Intent has been signed for a CNS-related medical device, expanding their strategic pipeline.
Read more →OGENOragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics has signed a Letter of Intent to license CardioDialysis™ technology from Sigyn Therapeutics, aiming to develop treatments for Traumatic Brain Injury (TBI) and chronic neurodegenerative diseases. This partnership positions Oragenics as the only company targeting TBI-induced inflammation on both sides of the blood-brain barrier. The agreement is contingent on due diligence and board approvals, with a target closing in 90 days.
Read more →OGENOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Oragenics has activated a second site for its Phase IIa clinical trial of ONP-002, aimed at treating concussion and mild traumatic brain injury (mTBI). The trial is designed to enroll 40 patients, with initial dosing occurring within 12 hours of injury. ONP-002 is a first-in-class intranasal neurosteroid that could potentially transform treatment options for millions affected by these conditions. The company anticipates a data readout by the end of 2026, which may support future FDA applications.
Read more →OGENOragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics, Inc. has initiated a Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (mTBI) with the first doses administered at Mackay Base Hospital in Australia. The drug is positioned to potentially become the first pharmacological treatment for concussion, addressing a significant medical need given the absence of current FDA-approved options. Enrollment is ongoing, with a total of 40 patients to be included in the trial. Positive early results bolster the company's confidence in the therapeutic potential of ONP-002, which aims to tackle underlying biological processes rather than just alleviate symptoms.
Read more →OGENOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics, Inc. has initiated patient dosing in its Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (mTBI). This milestone follows the activation of Mackay Hospital in Australia as the first clinical site. ONP-002 aims to provide a pharmacological treatment for concussion, a condition currently lacking approved therapies. The trial will evaluate safety and tolerability in patients receiving treatment within 12 hours of concussion.
Read more →OGEN▲ +11.2%on this news
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury Mackay Base Hospital activated
Oragenics, Inc. has initiated patient dosing in its Phase IIa clinical trial for ONP-002 aimed at treating mild traumatic brain injuries (mTBI) and concussions. This milestone was achieved at Mackay Hospital in Australia, with the first patient dosed shortly after the site activation. ONP-002, delivered intranasally, is designed to address brain injury biology rather than merely managing symptoms, and if successful, it could become the first approved medication for mTBI in a market projected to reach over $9 billion by 2030.
Read more →OGEN▼ -7.3%on this newsshared move
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics, Inc. announced that its audited financial statements included an unqualified audit opinion with a going concern explanation. This disclosure follows the filing of its Annual Report on Form 10-K for the year ended December 31, 2025. The company continues to develop its lead candidate, ONP-002, for concussion and mild traumatic brain injury.
Read more →OGENORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics, Inc. has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, highlighting significant operational and financial achievements. The company successfully completed a $16.5 million capital raise and regained compliance with NYSE American listings, marking a decisive transformation in its operations. Furthermore, in 2026, Oragenics received ethics approval to initiate patient dosing for its lead candidate, ONP-002, in Australia. The company also aims to expand its central nervous system pipeline and file an IND with the FDA for U.S.-based clinical trials.
Read more →OGEN▲ +8.5%on this newsshared move
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Oragenics, Inc. has announced the completion of the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia, marking a significant milestone in their clinical development process. This trial aims to evaluate the safety and preliminary effectiveness of ONP-002 for treating concussions and mild traumatic brain injuries. Two additional trial sites are under review and are expected to begin patient enrollment soon. The company emphasizes their commitment to disciplined execution in advancing ONP-002 through the clinical stages.
Read more →OGEN▼ -9.9%on this newsshared move
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
Oragenics, Inc. is considering the acquisition of additional assets in the CNS sector to enhance its platform focused on brain health and recovery. This expansion follows the positive progress of its lead candidate, ONP-002, which is currently undergoing Phase IIa clinical trials. Oragenics aims to leverage its proprietary intranasal delivery technology to establish a diversified CNS portfolio that synergizes with its existing offerings. However, no definitive agreements have been reached, and the success of any acquisition remains uncertain.
Read more →OGENOragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics has announced that it has received final HREC approval to begin a Phase IIa clinical trial for its investigational drug ONP-002, targeting concussion and mild traumatic brain injury (mTBI). This trial is notable as there are currently no FDA-approved pharmacological treatments for mTBI, representing a significant unmet medical need. The study will involve patient enrollment at three sites in Australia, with the aim to dose the first patient by the end of March 2026. If successful, ONP-002 could redefine treatment approaches by targeting the underlying biology of mTBI rather than merely providing symptomatic relief.
Read more →OGENOragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia All required regulatory approvals secured for tria
Oragenics, Inc. has announced the receipt of HREC approval to initiate a Phase IIa clinical trial for its drug candidate ONP-002, aimed at treating concussion and mild traumatic brain injury in Australia. This trial marks a significant step forward as ONP-002 could be the first pharmacological treatment for these conditions, which currently lack FDA-approved therapies. Patient enrollment is set to begin across three sites, with the first dosing expected before the end of March 2026. The company anticipates that positive outcomes from this trial may support future U.S. clinical trials pending FDA application.
Read more →OGEN▼ -5.2%on this news
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Oragenics is advancing ONP-002, a novel intranasal neurosteroid, as a potential first treatment for concussion and mild traumatic brain injury (mTBI). The company is preparing to initiate a Phase 2 clinical trial in Australia, despite delays caused by hospital consolidations. The projected global market for concussion therapies is expected to exceed $9 billion by 2030, highlighting the significant opportunity for ONP-002 if approved.
Read more →OGEN▼ -7.2%on this news
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Oragenics has partnered with DUCK FLATS Pharma to enhance its FDA IND readiness and clinical trial design for its intranasal concussion therapy, ONP-002. This collaboration aims to align their Phase 2a clinical trial in Australia with U.S. regulatory strategies. The partnership leverages DUCK FLATS Pharma's extensive experience in drug development to navigate the regulatory landscape effectively.
Read more →OGENOragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Oragenics, Inc. announced its participation in the SCOPE Summit 2026, a key conference for clinical research. The event, taking place from February 2-5 in Orlando, Florida, aligns with the company's upcoming Phase 2a trial of its concussion treatment, ONP-002. CEO Janet Huffman expressed enthusiasm for engaging with industry leaders to advance neurological care. The company aims to address significant unmet medical needs in concussion and mild traumatic brain injury.
Read more →OGENOragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Oragenics, Inc. will present at the Sequire Investor Summit 2026 in Puerto Rico from January 20-22. CEO Janet Huffman emphasized the importance of their ONP-002 clinical program, which targets concussion and mild traumatic brain injury, as there are no approved therapies available. The company is advancing ONP-002 through Phase 2a trials in Australia, with U.S. trials planned.
Read more →OGENOragenics Q3 2025 Shareholder Update Building on Solid Ground: From Vision to Execution Restoring Compliance, Advancing Innovation, Preparing for Clinical Milestones
Oragenics, Inc. reported positive operational and financial achievements in its Q3 2025 update, highlighting regained compliance with NYSE listing standards and the establishment of critical trial infrastructure. The company is set to initiate its Phase IIa clinical trial in Australia for its lead candidate, ONP-002, aimed at treating mild traumatic brain injury. Additionally, a strategic collaboration with Receptor.AI is expected to enhance the development of its broad neurological therapy pipeline. The management emphasizes disciplined execution and building a sustainable platform for various therapeutic applications.
Read more →OGENOragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Oragenics, Inc. has successfully regained compliance with the NYSE American's listing standards after resolving its stockholder equity deficiency. This follows a significant capital raise of $16.5 million, enabling the company to advance its lead clinical candidate, ONP-002, in concussion and mild traumatic brain injury treatments. With the financial stability restored, Oragenics is now concentrating on progressing into critical Phase II clinical trials in Australia and preparing for trials in the U.S.
Read more →OGENOragenics Q2 2025 Shareholder Update
Oragenics, Inc. has reported significant milestones in Q2 2025, focusing on its lead candidate ONP-002 for concussion treatment. The company aims to pioneer a new approach to neurotrauma care through its proprietary intranasal delivery technology. With a recent capital raise of $16.5 million, Oragenics is positioned to advance its clinical trials and explore strategic partnerships to enhance its market presence.
Read more →OGENOragenics Q2 2025 Shareholder Update Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion
Oragenics, Inc. has reported significant progress on its Brain-First Recovery Platform during Q2 2025, with strategic milestones and financial achievements positioning the company for future clinical trials. The lead candidate, ONP-002, aims to become the first FDA-approved pharmacological treatment for concussion, with plans for Phase IIa trials set to launch in Q3 2025. The company has also established valuable partnerships and secured funding to support its ambitious goals in neurotrauma care. Overall, Oragenics is positioning itself as a pioneer in the intranasal delivery of therapeutics for neurological conditions.
Read more →OGENOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
Oragenics, Inc. has selected Southern Star Research as its Clinical Research Organization for the Phase IIa trial of ONP-002, targeting mild traumatic brain injury. The trial will assess the safety and efficacy of the intranasal neurosteroid. With ethics approval secured, patient enrollment is expected to begin soon, marking a significant step in concussion treatment.
Read more →OGEN▲ +6%on this news
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics, Inc. has announced a manufacturing agreement with Sterling Pharma Solutions to produce its lead drug candidate, ONP-002, for concussion treatment. This partnership aims to ensure GMP-compliant supply ahead of the planned Phase IIb clinical trials set to begin next year. The collaboration is seen as a critical milestone for Oragenics in its clinical development strategy.
Read more →OGEN▲ +6.3%on this news
Oragenics Completes Approximately $16.5 Million Offering
Oragenics, Inc. has successfully closed a public offering of Series H Convertible Preferred Stock and Warrants, raising approximately $16.5 million. The funds will be used to advance the clinical development of ONP-002, an intranasal drug candidate for concussion treatment, among other corporate purposes. The offering reflects strong investor confidence in the company's strategy.
Read more →OGEN▼ -59.4%on this newsshared move
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Oragenics, Inc. has announced a public offering of up to $20 million in Series H Convertible Preferred Stock and accompanying Warrants. The offering aims to fund ongoing clinical trials for ONP-2, repay a bridge note, and support general corporate purposes. The offering is expected to close around July 2, 2025, pending customary conditions.
Read more →OGENOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
Oragenics, Inc. announced participation in two major events in June 2025: the BIO International Convention and the National Neurotrauma Society Symposium. Greg Gironda, Head of Business Development, will present the company's lead candidate, ONP-002, aimed at treating concussions. These events provide a platform for Oragenics to connect with industry leaders and promote its innovative intranasal therapeutics.
Read more →OGEN▼ -27.8%on this news
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
Oragenics, Inc. announced a One-for-Thirty reverse stock split approved by its Board of Directors. This action is set to take effect on June 3, 2025, and aims to increase the market price per share. The move is expected to align the company better with long-term investors and enhance its capital market presence.
Read more →OGEN▲ +8.9%on this news
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
Oragenics, Inc. has received approval from the Human Research Ethics Committee in Australia to initiate a Phase II clinical trial for ONP-002, a neuroprotective therapy aimed at treating mild traumatic brain injury (concussion). This marks a significant step in expanding their clinical development internationally. Patient enrollment could begin in the second quarter of 2025, with trials conducted in trauma emergency departments.
Read more →OGEN▲ +6.8%on this newsshared move
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Oragenics, Inc. will host a webinar on May 20, 2025, to discuss its ONP-002 clinical program aimed at treating concussions. The event will feature key executives presenting the unmet medical needs in concussion treatment and the potential of ONP-002 as a neuroprotective therapy. The company is advancing its Phase IIa clinical program, highlighting ONP-002's promising preclinical results.
Read more →OGENOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
Oragenics, Inc. will participate in the 15th Annual Traumatic Brain Injury Conference on May 5-6, 2025, in Boston. Dr. W. Frank Peacock will present updates on the HeadSMART II trial, which focuses on mild traumatic brain injury. This trial is significant for advancing detection and management strategies for TBI. The collaboration with BrainBox Solutions aims to integrate diagnostics with intranasal therapies.
Read more →OGEN▲ +6.7%on this news
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
Oragenics, Inc. has submitted a clinical trial protocol to the Health and Disability Ethics Committee in New Zealand for its Phase IIa trial evaluating ONP-002, a neurosteroid therapy for concussion treatment. This submission is a significant step in addressing the lack of existing concussion therapies. If approved, patient enrollment will begin at Christchurch Hospital, a major research institution. The therapy has shown positive results in preclinical models and was deemed safe in Phase I testing.
Read more →OGEN▼ -7.1%on this newsshared move
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
Oragenics, Inc. recently participated in the 3rd Nasal Formulation & Delivery Summit, where Chief Medical Officer Dr. James Kelly contributed to discussions focused on advancements in intranasal drug delivery. The conference emphasized innovations in CNS therapeutics and emergency treatments. During the event, Dr. Kelly highlighted Oragenics' work on ONP-002, a novel neurosteroid aimed at improving outcomes for patients with mild traumatic brain injury. The company's presence at this summit reinforces its dedication to pioneering non-invasive therapies for brain-related disorders.
Read more →OGENOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Oragenics, Inc. has provided a Q1 2025 shareholder update detailing strategic advancements and financial progress. The company highlighted key accomplishments, including a strategic partnership with BRAINBox Solutions, regulatory submissions for its lead candidate ONP-002, and successful fundraising efforts. CEO Janet Huffman expressed optimism in the potential of ONP-002 as a transformative treatment for concussions, addressing an unmet need. The company is focused on advancing ONP-002 rapidly through critical clinical stages in the coming months.
Read more →OGENOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Oragenics, Inc. has filed its 2024 Annual Report on Form 10-K, detailing its financial performance for the year ended December 31, 2024. The company's consolidated financial statements received an unqualified audit opinion, although they included an explanatory note on their ability to continue as a going concern. Oragenics focuses on innovative treatments, particularly in the areas of concussion and infectious diseases. They are active in developing intranasal delivery systems for their drug candidates.
Read more →OGENOragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. announced the submission of its Investigator's Brochure for a Phase II clinical trial of ONP-002 to be conducted in Australia. ONP-002 is a novel intranasal neurosteroid showing promising preclinical results for mild traumatic brain injury (mTBI). The upcoming trial will assess the drug's feasibility and safety in patients, intending to provide a much-needed treatment for concussions, a condition with no current FDA-approved therapies. Janet Huffman, Interim CEO of Oragenics, highlighted the submission as a critical advancement towards the clinical trial's initiation.
Read more →OGENOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Oragenics, Inc. announced that Dr. James Kelly will present at the Emergencies in Medicine Conference, focusing on concussion treatment advancements. His presentation will highlight ONP-002, a novel intranasal neurosteroid, and the 'Trigger-to-Treat' program designed for acute concussion management. The conference aims to gather healthcare professionals to discuss innovations in emergency medicine, particularly in concussion care. Oragenics' collaboration with BRAINBox Solutions intends to enhance diagnostic precision and patient stratification in clinical trials.
Read more →OGENOragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
Oragenics, Inc. announced that Dr. James Kelly, its Chief Medical Officer, has joined the Medical Board of The Leigh Steinberg Foundation, focusing on concussion and brain health. Dr. Kelly is recognized for his extensive work in traumatic brain injury (TBI) research and treatment, previously leading the National Intrepid Center of Excellence. His appointment is seen as crucial for advancing initiatives related to brain health education and improved access to care. Oragenics is committed to developing ONP-002, an intranasal treatment for concussion, enhancing patient outcomes.
Read more →OGEN▼ -6.8%on this news
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Oragenics, Inc. has announced a strategic partnership with BRAINBox Solutions to create the first intranasal therapy for mild traumatic brain injury (mTBI), also known as concussion. The partnership intends to integrate advanced diagnostic technologies with Oragenics' therapeutic candidate, ONP-002, to improve concussion care. This collaboration aims to provide rapid diagnosis and targeted treatment to enhance patient outcomes, addressing a significant unmet need in TBI management. Both companies are at the forefront of developing innovative solutions in the field of neurology, which affects millions annually.
Read more →OGENOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Oragenics, Inc. has announced that its Chief Medical Officer, Dr. James P. Kelly, will participate as a panelist at the 12th Annual Brain Health Summit during the Super Bowl weekend in New Orleans. The summit will focus on increasing awareness and advancing treatment for traumatic brain injuries (TBI) in athletics. Dr. Kelly's involvement highlights Oragenics' innovative approaches, particularly their neurosteroid ONP-002, aimed at addressing concussion treatment. The event will gather leading experts and advocates to foster collaboration and drive change in brain health care.
Read more →OGENOragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
Oragenics, Inc. has updated shareholders on its strategic progress since a capital raise in September 2024, announcing the appointment of Janet Huffman as interim CEO. The company has made notable advancements, including enhancements to the formulation and delivery devices for its drug candidate, ONP-002, and has made strides in preparing for Phase II clinical trials in Australia, with the goal of dosing the first patient by early Q2 2025. The leadership transition is viewed positively by the Board, indicating confidence in Huffman's ability to guide the company forward.
Read more →OGEN▲ +5.9%on this news
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Oragenics, Inc. announced the conversion of its remaining Series A and Series B Preferred Shares into common stock, which simplifies its capital structure and eliminates approximately $2.35 million in liquidation preference. This significant change is aimed at removing an overhang on the company's stock and aligns with its commitment to creating long-term value for shareholders. CFO Janet Huffman described the conversion as pivotal for strengthening the company’s foundation for future growth, particularly in developing treatments for neurological and rare diseases.
Read more →OGENOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics, Inc. announced that it will present at the Centurion One Capital 2nd Annual Bahamas Summit, taking place from October 22-23, 2024. Michael Redmond, the President of Oragenics, will lead a corporate presentation followed by a Q&A session on October 22 at 1:20 pm ET. The company is recognized for its focus on developing nasal delivery medications aimed at treating neurological disorders and infections, including mild traumatic brain injury and Niemann Pick Disease Type C.
Read more →OGEN▲ +6.4%on this news
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oragenics, Inc. has provided an update on its concussion drug ONP-002, highlighting significant milestones achieved throughout 2024. The company has successfully prepared for Phase II clinical trials after positive results from Phase I, including strong safety profiles and successful completion of regulatory studies. The innovative intranasal delivery approach aims to offer rapid, effective treatment for concussions. With recent financings and a focus on clinical trial preparations in Australia, Oragenics is poised to make further advancements in concussion therapy.
Read more →OGEN▼ -9.2%on this newsshared move
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Oragenics Inc. has announced the completion of a significant study for their new concussion drug, ONP-002, which utilizes nasal delivery to enhance treatment efficacy. The study demonstrated promising results, showing effective targeting of nasal areas linked to brain absorption, potentially enabling faster treatment after head injuries. The company is now preparing to initiate Phase II clinical trials, aiming to administer the drug to concussion patients within 8 hours of injury. This development comes at a time when there are currently no specific pharmaceutical treatments available for concussions.
Read more →OGEN▼ -8.8%on this news
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. has successfully closed a public offering of 3,078,378 shares of common stock and pre-funded warrants, generating approximately $4.45 million in gross proceeds. The funds will be allocated towards the development of their ONP-002 product candidate, as well as general corporate purposes. With a focus on intranasal pharmaceuticals designed to treat neurological disorders, Oragenics positions itself within a unique sector of biotechnology. The offering was conducted under SEC regulations, with Dawson James Securities, Inc. acting as the placement agent.
Read more →OGEN▼ -46.2%on this newsshared move
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. announced a public offering of 8,106,584 shares of common stock priced at $0.55 per share, anticipated to close around September 5, 2024. The expected gross proceeds from this offering are approximately $4.45 million, which will be utilized primarily for the development of the ONP-002 product candidate and for corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent for this transaction, which was conducted under a registration statement filed with the SEC.
Read more →OGENOragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Oragenics Inc. has successfully completed the spray-dried formulation and filling of its intranasal device for ONP-002, targeting concussions. This innovative drug is designed to be delivered intranasally, potentially making it the first pharmaceutical treatment for concussion. The upcoming Phase IIa clinical trial in Australia will involve 40 patients and aims to initiate treatment swiftly after injury, utilizing both the drug and a placebo. The development highlights Oragenics' focus on addressing unmet medical needs in concussion treatment.
Read more →OGEN▼ -21.5%on this news· ran to -34% by day 3shared move
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics, Inc. has announced significant advances in its lead candidate ONP-002, intended for concussion treatment, with plans for Phase 2 trials expected to start in Q4 2024. The drug demonstrates stability across varying temperatures and recently cleared FDA-required safety testing, paving the way for its development. However, the company is currently non-compliant with certain NYSE American listing standards and has until October 18, 2025, to rectify this issue, potentially impacting its operations and investor relations. The appointment of key medical advisors aims to strengthen clinical trial oversight as Oragenics works to address these challenges.
Read more →OGEN▼ -19.3%on this news· ran to -54% by day 3shared move
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics, Inc. announced that its concussion treatment candidate, ONP-002, exhibits stability across a wide temperature range, eliminating the need for cold storage. This stability is crucial for real-world applications, such as in contact sports or military operational environments. The company has completed the drug batch synthesis for its planned Phase II clinical trial. This product aims to address the significant unmet medical need for effective concussion treatments, as there are currently no FDA-approved options available.
Read more →OGEN▲ +48.6%on this news· ran to +59% by day 1shared move
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Oragenics, Inc. announced that its lead candidate for concussion treatment, ONP-002, has successfully completed a genotoxicity study, indicating it does not cause DNA damage or cancer risk in animal models. The results suggest a promising safety profile as the company plans to move forward with a Phase II clinical trial. Concussions represent a significant global healthcare challenge, with millions reported annually, and ONP-002 aims to address this unmet need in neurological health.
Read more →OGEN▲ +11.7%on this news· ran to +131% by day 3shared move
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. announced that its lead drug candidate, ONP-002, successfully passed FDA-required tests for cardiotoxicity. This advancement is crucial as it enables the company to move forward with planning Phase II clinical trials. ONP-002 aims to treat concussions, a condition affecting an estimated 69 million people globally each year. The drug targets the brain through intranasal delivery, indicating a novel approach to addressing neurological disorders linked with concussions, including long-term disabilities. The company emphasizes safety as a top priority as they proceed with future evaluations.
Read more →OGEN▲ +11.3%on this news
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
Oragenics, Inc. announced an improved formulation for its intranasal drug candidate, ONP-002, aimed at treating concussed patients. The new formulation enhances drug absorption and bioavailability, allowing for quicker entry into the brain through the nasal cavity. A Phase II clinical study is planned to evaluate the safety and effectiveness of this drug based on various patient outcomes. This advancement addresses a significant medical need, considering the millions of concussions reported annually worldwide.
Read more →OGENOragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics has developed a prototype of an automated intranasal device for administering their drug candidate, ONP-002, to concussed patients. The device aims to assist patients who may be confused or unconscious in the acute stages of injury by allowing medical personnel to deliver the treatment. A forthcoming Phase II study is set to evaluate the efficacy of ONP-002 on patient outcomes. The company highlights the importance of addressing the unmet medical need in concussion treatment, as a significant number of patients experience severe symptoms and long-term complications.
Read more →OGEN▼ -9.4%on this news· ran to -31% by day 3shared move
Oragenics, Inc. Announces Proposed Public Offering
Oragenics, Inc. has announced a proposed public offering of its common stock to fund the development of its ONP-002 product candidate and for general corporate purposes. The offering will be managed by Dawson James Securities and is subject to market conditions, which creates uncertainty about its completion and terms. Interested parties are advised to read the prospectus supplement detailing the offering before investing. Oragenics specializes in the development of intranasal pharmaceuticals targeting neurological disorders and other conditions.
Read more →OGEN▼ -5.2%on this news· ran to -35% by day 3shared move
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
Oragenics, Inc. announced that the NYSE American has accepted its compliance plan to regain listing standards. The acceptance came after a review of the company's submitted plan on May 17, 2024, demonstrating a reasonable ability to make progress by October 18, 2025. The company, focused on intranasal pharmaceuticals, will be monitored quarterly for compliance, and failing to meet these standards could lead to delisting.
Read more →OGEN▼ -17.4%on this news· ran to -30% by day 3
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
Oragenics, Inc. has appointed Dr. William 'Frank' Peacock as Chief Clinical Officer, who will oversee the company's Phase II clinical trial for ONP-002, a drug aimed at treating concussions. The drug has already shown safety in a completed Phase I study and is designed for intranasal delivery targeting the brain. Dr. Peacock brings extensive experience in emergency medicine and concussion research, enhancing Oragenics' potential for success in this area. The company is addressing a significant unmet medical need as concussions affect millions worldwide.
Read more →OGEN▲ +42.1%on this news· ran to +87% by day 1shared move
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
Oragenics, Inc. announced it will host a webinar on Neurotrauma Medicine on May 20, 2024. The panel will cover Traumatic Brain Injury (TBI) and discuss ONP-002, a neurosteroid intended to treat mild TBI. This session aims to highlight the unmet medical needs associated with concussions and other neurological disorders. The company will also review outcomes from preclinical and Phase I trials, alongside details regarding an upcoming Phase II clinical trial.
Read more →OGENOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
Oragenics, Inc. has announced its preparations for a Phase II clinical trial of its lead drug candidate, ONP-002, designed to treat mild Traumatic Brain Injury (concussion). The company is enhancing the formulation to optimize its intranasal delivery, ensuring effective brain targeting. The trial will take place in emergency departments at level one trauma centers, supported by a partnership with Avance Clinical Pty Ltd. Positive preclinical studies have indicated that ONP-002 can significantly improve outcomes following brain injuries.
Read more →OGEN▲ +24.1%on this news· ran to +70% by day 3
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
Oragenics, Inc. has announced a partnership with Avance Clinical to conduct a Phase II clinical trial in Australia for its lead drug candidate, ONP-002, targeting mild Traumatic Brain Injury. The drug, which utilizes an intranasal delivery system, has demonstrated safety in previous trials. Experts highlight the significance of this research, particularly in light of Australia's high incidence of sports-related concussions. This initiative aims to advance treatment options for concussion, a prevalent health concern with millions of cases reported globally each year.
Read more →OGENOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Oragenics, Inc. has announced that it is not in compliance with the NYSE American continued listing standards due to insufficient stockholder equity. The company reported $3.2 million in equity while the requirements stipulate at least $4 million under certain conditions. Oragenics must submit a compliance plan by May 18, 2024, and regain compliance by October 18, 2025, or face potential delisting. Despite the notice, trading will continue under the symbol 'OGEN' with a 'below compliance' designation.
Read more →OGENOragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion (
Oragenics, Inc. has appointed Dr. James Kelly as Chief Medical Officer to supervise its Phase II clinical trials for ONP-002, aimed at treating mild Traumatic Brain Injury (TBI), commonly known as concussion. Dr. Kelly brings extensive experience from his previous roles, including Executive Director at the Marcus Institute for Brain Health. The trials aim to demonstrate the drug's safety and efficacy in improving patient outcomes, building on successful results from a prior Phase I study. The company is currently preparing for the trial while addressing manufacturing and formulation at GMP facilities.
Read more →OGENOragenics Announces Closing of Public Offering
Oragenics, Inc. has announced the completion of its public offering, securing $2.1 million from the sale of 1,400,000 shares at $1.50 each. The company plans to allocate these proceeds primarily towards the development of ONP-002, a drug aimed at treating mild traumatic brain injuries, among other corporate purposes. Additionally, underwriters were granted an option to purchase more shares, indicating potential further investment.
Read more →OGEN▼ -22.5%on this news· ran to -55% by day 1shared move
Oragenics Announces Proposed Public Offering SARASOTA, Fla. - [
Oragenics, Inc. announced a proposed underwritten public offering of its common stock, which may also include pre-funded warrants. This move aims to finance the continued development of ONP-002, a drug compound designed for treating mild traumatic brain injuries, and for general corporate purposes. The company will provide additional details through a preliminary prospectus supplement. However, the success of the offering is subject to market conditions and other risks.
Read more →OGEN▼ -22.5%on this news· ran to -55% by day 1shared move
Oragenics Announces Pricing of Public Offering
Oragenics, Inc. has announced the pricing of a public offering of 1,400,000 shares of its common stock at a price of $1.50 per share, expected to close on March 1, 2024. The offering is anticipated to generate gross proceeds of approximately $2.1 million, which will be utilized to further develop its unique neurosteroid drug, ONP-002, aimed at treating mild traumatic brain injuries. Additionally, underwriters have been granted an option to purchase up to 210,000 additional shares. The offering complies with SEC regulations as detailed in a prospectus filed earlier this year.
Read more →OGEN▼ -5.5%on this news· ran to -16% by day 1
Oragenics, Inc. Announces Leadership Transition (
Oragenics, Inc. announced a leadership transition due to the separation agreement with CEO Kimberly Murphy, effective February 12, 2024. Murphy will remain with the company as a board member while Charlie Pope moves into the role of Executive Chairman on an interim basis. Michael Redmond has been appointed Interim Principal Executive Officer. The board expressed appreciation for Murphy's leadership during the company's shift towards its neurology assets.
Read more →OGEN▲ +24.1%on this news· ran to +58% by day 1shared move
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement SARASOTA, Fla.-(BUSINESS WIRE)-Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle ph
Oragenics, Inc. has announced the expiration of its investment banking engagement agreement, choosing not to renew it in light of current market conditions. The company is focused on developing intranasal nanoparticle pharmaceuticals for neurological disorders, including treatments for mild traumatic brain injury. This announcement raises concerns about its financial strategy and market positioning during a challenging economic landscape.
Read more →OGEN▼ -6.1%on this news· ran to +62% by day 3shared move
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
Oragenics, Inc. (NYSE American: OGEN) is preparing to launch Phase II clinical trials for its drug ONP-002, which targets mild traumatic brain injury (concussion) through an innovative intranasal delivery system. Following a 40-patient Phase I study that confirmed the drug's safety, the company is moving forward to synthesize and formulate ONP-002 for patient treatment shortly after concussion diagnosis. The drug's neuroprotective profile and potential to improve outcomes highlight its promise in addressing a significant public health issue, with approximately 69 million concussions reported annually worldwide.
Read more →OGENOragenics Announces Termination of At-The-Market Offering Program
Oragenics, Inc. has announced the termination of its at-the-market equity offering program, which will take effect on January 30, 2024. The company stated that no sales will be conducted under this program during the 5-day termination process. Oragenics is focused on developing nasal delivery pharmaceuticals, including its neurosteroid ONP-002 for treating Mild Traumatic Brain Injury and an intranasal COVID-19 vaccine candidate. The company cites its research collaboration with the NIH and NRC for these projects.
Read more →OGEN▲ +20.5%on this news
Oragenics Completes Acquisition of Odyssey Health's Neurological Assets
Oragenics, Inc. has completed the acquisition of neurological assets from Odyssey Health, which includes ONP-002, an intranasal drug candidate for treating concussions. The acquisition expands Oragenics' product pipeline and aims to address the unmet medical need in concussion treatments, with market forecasts indicating substantial growth. The company plans to move into Phase 2 clinical trials for ONP-002, following positive Phase 1 results. Michael Redmond has been appointed as President of Oragenics to oversee the neurology product pipeline and ensure integration of Odyssey’s development team.
Read more →OGENOragenics Issues Update to Shareholders TAMPA, Fla. (
Oragenics announced an update to shareholders concerning their acquisition of Odyssey Health's assets, expected to close in December 2023. The acquisition is aimed at enhancing shareholder value by utilizing Odyssey's neurological drug therapies, particularly for concussion treatment and Niemann Pick Disease Type C. The company plans to increase its authorized shares of capital stock to facilitate this acquisition and is pursuing various funding options to support its research and development initiatives. Despite concerns about potential dilution, the company remains optimistic about its prospects in advancing intranasal therapies.
Read more →OGEN▲ +13%on this news
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate Gains Nasal Delivery Technologies and Expands Product Pipeline TAMPA, Fla. and LAS VEGAS, Nev. (
Oragenics, Inc. is set to acquire the neurological drug technology pipeline of Odyssey Health, which includes drug candidates for treating concussions and Niemann Pick Disease Type C. The acquisition features an innovative nasal delivery system that could lead to improved patient outcomes with rapid drug uptake. Key candidate ONP-002 has shown promising results in preclinical studies and has completed Phase 1 clinical trials, preparing for Phase 2. The transaction, valued at $1.0 million and shares, is expected to close in Q4 2023 pending shareholder approvals.
Read more →OGENOragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets Potential to Protect Against Dental Caries, a Global Health Issue TAMPA, Fla. (
Oragenics, Inc. has entered a partnership with Lantern Bioworks focused on dental caries prevention through replacement therapy. This agreement follows the successful testing of Oragenics' biological samples, which could transform oral health management. As part of the agreement, Oragenics will receive a $50,000 cash payment and has the opportunity to acquire one million shares of Lantern Bioworks. Additionally, they will benefit from a 10% royalty on net income from products developed from the transferred assets over ten years.
Read more →OGENORAGENICS, INC. ANNOUNCES PRIVATE PLACEMENT TAMPA, FL, (
Oragenics, Inc. announced the closing of a private placement that raised approximately $840,000 through the sale of common stock and Series E Preferred Stock. The company plans to use the net proceeds from this offering for general corporate purposes. Additionally, Oragenics intends to propose an amendment to increase its authorized shares from 4.16 million to 350 million at the upcoming annual shareholders' meeting. The company is focused on developing treatments for infectious diseases, including COVID-19 and antibiotic-resistant bacteria.
Read more →OGENOragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM TAMPA, Fla. (
Oragenics has received a grant from CQDM to develop a variant-agnostic COVID-19 vaccine candidate. This project builds on their existing intranasal vaccine NT-CoV2-1, in collaboration with the National Research Council of Canada and Inspirevax. The funding aims to support the creation of stable CHO pools expressing new vaccine antigens for mucosal immunization, potentially accelerating advancements in addressing evolving SARS-CoV-2 variants. The initiative highlights the importance of collaborative efforts in advancing biopharmaceutical research and development.
Read more →OGENOragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE Potentially Addresses Life-Threatening Antibiotic-Resistant Infections TAMPA, Fla. (
Oragenics, Inc. has announced positive results from third-party laboratory testing of its lantibiotics compounds, demonstrating effectiveness against antibiotic-resistant pathogens, specifically MRSA and VRE. The company noted that these compounds remain effective even against strains resistant to existing antibiotics. This development is part of Oragenics' commitment to addressing life-threatening infections through innovative antibiotic solutions. The favorable outcomes from their collaboration with Linnaeus Bioscience are seen as a significant step toward moving these compounds into clinical development.
Read more →OGENOragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team TAMPA, Fla. (
Oragenics, Inc. has appointed Janet Huffman as Chief Financial Officer, effective March 7, 2023. Huffman brings over a decade of healthcare financial leadership to the role, having worked with various public and private companies. Her expertise in raising capital and navigating mergers and acquisitions is expected to support Oragenics' growth strategy in combating infectious diseases, including a focus on its intranasal COVID-19 vaccine candidate. Huffman expressed eagerness to leverage her network to enhance the company's financial position and stakeholder value.
Read more →OGENOragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate Licensing milestones provides opportunity to expand vaccine program TAMPA, Fla. (
Oragenics, Inc. has entered into an exclusive global license agreement with Inspirevax Inc. to develop its lead intranasal COVID-19 vaccine candidate, NT-CoV2-1, utilizing Inspirevax's mucosal adjuvant, BDX301. This partnership marks a significant opportunity for Oragenics to expand its vaccine initiatives, as both companies will collaborate through a Joint Development Committee. Preclinical results have shown promising safety and immunogenicity for NT-CoV2-1, with plans for further clinical study updates expected in mid-2023. The agreement indicates Oragenics' commitment to addressing the unmet medical need for intranasal COVID-19 vaccination.
Read more →OGENOragenics, Inc. Receives NYSE American Notice TAMPA, FL. (
Inc. Receives NYSE American Notice FL. (December 20, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice (the "Notice") on Decemb
Read more →OGENOragenics, Inc. Announces New Chair TAMPA, FL. (
Inc. Announces New Chair FL. (December 19, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed C
Read more →OGENOragenics Issues Letter to Shareholders TAMPA, Fla. (
Issues Letter to Shareholders Fla. (September 30, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its Presi
Read more →OGENOragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune resp
Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate Fla. (August 24, 2022) Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced
Read more →OGENOragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer TAMPA, Fla. (
Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer Fla. (June 23, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announ
Read more →OGENMAY 17, 2022 Oragenics Issues Letter to Shareholders TAMPA, Fla. (
Issues Letter to Shareholders Fla. (May 17, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: My Fellow Shareholders, am pleased to share wit
Read more →OGENOragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses extends current licensing and collaboration agreement to include rapid of intranasal vaccine candidates against future variants Fla.-(BUSINESS WIRE)- Oragenics, Inc. (NYSE American: OGEN) ("Orag
Read more →OGENOragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candida
Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate Fla. (March 10, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Orage
Read more →OGENOragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum TAMPA, Fla. (
Announces Adjournment of Annual Meeting of Shareholders Fla. (January 26, 2022) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced that the Company's reconvened Annual Meeting of Shareholders (the "Annual Meeting"), on January 25, 2022, at 4:00 p.m
Read more →OGENOragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate Intranasal and Intramuscular Formulations were Assessed with Novel Adjuvants TAMPA, Fla.
Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate and Intramuscular Formulations were Assessed with Novel Adjuvants Fla. (December 1, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Compan
Read more →OGENOragenics A nnounces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum TAMPA, Fla. (
Announces Adjournment of Annual Meeting of Shareholders Fla. (November 23, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced that the Company's Annual Meeting of Shareholders (the "Annual Meeting"), on November 22, 2021, at 9:00 a.m. was co
Read more →OGENOragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. TAMPA, Fla. (
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. TAMPA, Fla. (October 4, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced
Read more →OGENOragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate Intranasal and Intramuscular Formulations to be Assessed with Novel Adjuvants TAMPA, Fla. (
Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate and Intramuscular Formulations to be Assessed with Novel Adjuvants Fla. (September 15, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today ann
Read more →OGENOragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants New data supports Company's approach to COVID-19 vaccine development. TAMPA (
SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants data supports Company's approach to COVID-19 vaccine development. (August 30, 2021) - Oragenics, Inc. (NYSE American: OGEN) (the Company) announces that the stabilized
Read more →OGENOragenics Announces Postponement of Annual Meeting of Shareholders TAMPA, Fla. (
Announces Postponement of Annual Meeting of Shareholders Fla. (August 24, 2021) - Oragenics, Inc. (NYSE American: OGEN) Oragenics, Inc. ("Oragenics" or the "Company") today announced the Company's reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was ad
Read more →OGENOragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines Agreement provides Oragenics with antigen expression cell lin
Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Agreement provides Oragenics with antigen expression cell line technology capable of producing spike proteins within six to eight weeks o
Read more →OGENOragenics Issues Letter to Shareholders Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine
Issues Letter to Shareholders Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences (May 18, 2021) - Oragenics, Inc. (NYSE American: OGEN)
Read more →OGENOragenics Announce Changes in Management and Board of Directors TAMPA, Fla. (
Announce Changes in Management and Board of Directors Fla. (May 3, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced that on May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursu
Read more →OGENORAGENICS ANNOUNCES RECENT CAPITAL RAISE AND WARRANT EXERCISES TOTALING $21.9 MILLION AND THE REDEMPTION OF ITS SERIES C PREFERRED STOCK TAMPA (
ANNOUNCES RECENT CAPITAL RAISE AND WARRANT EXERCISES TOTALING $21.9 MILLION AND THE REDEMPTION OF ITS SERIES C PREFERRED STOCK (February 12, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced it has raised approximately $20 million from the s
Read more →OGENSARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice Data supports the Company's approach to COVID-19 vaccine development TAMPA, Fla. (
Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective supports the Company's approach to COVID-19 vaccine development Fla. (February 2, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announces that the stabilized pre-fusion spik
Read more →OGENJANUARY 7, 2021 ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT TAMPA (
ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT (January 7, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced entering into a material transfer agreement with Adjuvance Technologies Inc. for
Read more →OGENORAGENICS ANNOUNCES CLOSING OF $6.5
ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced, the closing of its previously
Read more →OGENORAGENICS, INC. ANNOUNCES $6.5 MILLION REGISTERED DIRECT OFFERING TAMPA, FL, (
INC. ANNOUNCES $6.5 MILLION REGISTERED DIRECT OFFERING FL, (December 24, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announce
Read more →OGENORAGENICS ANNOUNCES CLOSING OF $6.0
ANNOUNCES CLOSING OF $6.0 MILLION UNDERWRITTEN PUBLIC OFFERING Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced, the closing of its previous
Read more →OGENORAGENICS PRICES $5.25
PRICES $5.25 MILLION COMMON STOCK OFFERING INC. (NYSE AMERICAN: OGEN) ("Oragenics" or the "Company"), a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the pricing of an underwritten public offering
Read more →OGENOragenics Announces Proposed Underwritten Public Offering
Announces Proposed Underwritten Public Offering - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced that it has commenced a propo
Read more →OGENFDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine Re-Affirms Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21 TAMPA (
Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21 (October 6, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced receipt of f
Read more →OGENOragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine TAMPA (
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine TAMPA (September 28, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") provides an update on U.S. federal government and other funding options the Company is pursuing in order to adv
Read more →OGENOragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference TAMPA, Fla. (
Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference Fla. (September 11, 2020) - Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel c
Read more →OGENoragenics signs process Development and Manufacturing Agreement with Avid Bioservices for Coronavirus Vaccine Avid Well Positioned to Meet Significant Scale-Up Requirements for NIH-Licensed SARS-CoV-2 Spike Protein Vacci
signs process Development and Manufacturing Agreement with Avid Bioservices for Coronavirus Vaccine Well Positioned to Meet Significant Scale-Up Requirements for NIH-Licensed SARS-CoV-2 Spike Protein Vaccine Candidate FL and TUSTIN, CA, August 20, 2020 - Oragenics, Inc. (NYSE A
Read more →OGENPreclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies Recently published paper supports the Company's approach to COVID-19 vaccine development TAMPA (
Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies published paper supports the Company's approach to COVID-19 vaccine development (July 22, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announ
Read more →OGENOragenics Provides Update on SARS-CoV-2 (COVID-19) Program Terminates AG013 Oral Mucositis Development Program TAMPA (
Provides Update on SARS-CoV-2 (COVID-19) Program AG013 Oral Mucositis Development Program (July 10, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or "the Company") today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced
Read more →OGENOragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing "Spike Protein"
Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing Fla-May 4, 2020 - Oragenics, Inc. (NYSE American: OGEN), (the "Company" or "Oragenics"), today announced its acquisition of Noachis Terra Inc., following its en
Read more →OGENOragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head Fla-April 15, 2020 - Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective t
Read more →OGENORAGENICS, INC. ANNOUNCES COMPLETION OF ENROLLMENT OF ITS PHASE 2 CLINICAL TRIAL FOR AG013
INC. ANNOUNCES COMPLETION OF ENROLLMENT OF ITS PHASE 2 CLINICAL TRIAL FOR AG013 IN ORAL MUCOSITIS Fla., December 2, 2019 - Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucosi
Read more →OGENORAGENICS
INC. TO PRESENT AT THE BIO INVESTOR FORUM Fla., October 22, 2019 - Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will be presenting at the BI
Read more →OGENOragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019 TAMPA, Fla. September 30, 2019 - (BUSINESS WIRE) Oragenics, Inc. (NYSE American: OGEN) ( Oragenics ), a leader in the development of novel antibiotics
Read more →OGENORAGENICS, INC. ANNOUNCES PHASE 2 CLINICAL TRIAL OF AG013 REACHES ENROLLMENT OF 158
ORAGENICS, INC. ANNOUNCES PHASE 2 CLINICAL TRIAL OF AG013 REACHES ENROLLMENT OF 158 PATIENTS TAMPA, Fla., September 25, 2019 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral muco
Read more →OGENORAGENICS, INC. TO PRESENT INTERIM DATA ON AG013
ORAGENICS, INC. TO PRESENT INTERIM DATA ON AG013 AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS TAMPA, Fla., September 23, 2019 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for
Read more →OGENSafe Harbor Statement Certain statements made in this presentation include forward-looking actions that Oragenics, Inc. ("Oragenics," or the "Company") anticipates based on certain assumptions. These statements are indic
Investor Presentation Alan F. Joslyn, PhD President & CEO 813 286 7900 ext 232 ajoslyn@oragenics.com Oragenics, Inc. 4902 Eisenhower Blvd., Suite 125 Tampa, FL 33634 www.oragenics.com NYSE American: OGEN Exhibit 99.1 Safe Harbor Statement Certain statements made in this presen
Read more →OGENOragenics Announces Closing of $12.5 Million Underwritten Public Offering
Oragenics Announces Closing of $12.5 Million Underwritten Public Offering TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announce
Read more →OGENORAGENICS ANNOUNCES PRICING OF $12.5
ORAGENICS ANNOUNCES PRICING OF $12.5 MILLION UNDERWRITTEN PUBLIC OFFERING TAMPA, Fla. (BUSINESS WIRE) Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced t
Read more →OGENOrganics Announces Proposed Underwritten Public Offering
Organics Announces Proposed Underwritten Public Offering TAMPA, Fla. (BUSINESS WIRE) Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has commen
Read more →OGENOragenics, Inc. Announces Enrollment of 60 th Patient in Clinical Trial
Oragenics, Inc. Announces Enrollment of 60th Patient TAMPA, Fla. (BUSINESS WIRE) Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis , today announces the enrollment of the
Read more →OGENORAGENICS, INC. RECEIVES CLEARANCE TO ENROLL PATIENTS IN BELGIUM INTO ITS PHASE 2 CLINICAL TRIAL OF AG013
ORAGENICS, INC. RECEIVES CLEARANCE TO ENROLL PATIENTS IN BELGIUM INTO ITS PHASE 2 CLINICAL TRIAL OF AG013 FOR ORAL MUCOSITIS TAMPA, Fla., October 17, 2018 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effe
Read more →OGENOragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the Company ) today announced the closing of an underwritten pu
Read more →OGENOragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering
Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the Company ) today announced the pricing of an underwritten public offering of units for gross proceeds of $
Read more →OGENOragenics Reports Positive Interim Safety Analysis Results From Its Phase 2 Clinical Trial of AG013 for Oral Mucositis TAMPA
Oragenics Reports Positive Interim Safety Analysis Results From Its Phase 2 Clinical Trial of AG013 for Oral Mucositis TAMPA, May 30, 2018 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments
Read more →OGENOragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140
Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140 May 23, 2018 02:00 PM Eastern Daylight Time Fla. (BUSINESS WIRE) Oragenics, Inc. (NYSE American: OGEN) (the Company ), a clinical stage biotechnology company, today announced that the Uni
Read more →OGENOragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering
Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the Company ) today announced that it has entered into a securities purchase agreement with certain new instit
Read more →OGENOragenics, Inc. Announces Reverse Stock Split
Oragenics, Inc. Announces Reverse Stock Split TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the Company ) today announced a reverse split of its common stock, $0.001 par value, at a ratio of 1 for 10, effective January 19, 2018 (the
Read more →OGENOragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards
Oragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the Company ) today announced receipt of notification from the NYSE American LLC (the Exchange ) that the
Read more →OGENOragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity Also amends Exclusive Channel Collaboration (ECC) Agreements with Intrexon TAMPA
Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity Also amends Exclusive Channel Collaboration (ECC) Agreements with Intrexon TAMPA, November 9, 2017 Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biot
Read more →OGENOragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement TAMPA
Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement TAMPA, July 26, 2017 Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biotechnology company, today announced that it has completed the second closing contemplated by the previou
Read more →OGENOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN the Company ) today announced receipt of notification from the NYSE MKT LLC (the Exchan
Read more →OGENOragenics Announces $3.0 Million Preferred Stock Private Placement and $2.4 Million Loan TAMPA
Oragenics Announces $3.0 Million Preferred Stock Private Placement and $2.4 Million Loan 2017 Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biotechnology company, today announced that it has entered into a securities purchase agreement with three accredited investors, to p
Read more →OGENU.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis TAMPA, FL
U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis TAMPA, FL, November 21, 2016 Oragenics (NYSE:MKT OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral m
Read more →OGENOragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment TAMPA, FL
Oragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment TAMPA, FL, August 30, 2016 Oragenics (NYSE:MKT OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatme
Read more →OGENOragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections TAMPA, FL
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile TAMPA, FL, August 23, 2016 Oragenics (NYSE:MKT OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today an
Read more →OGENOragenics, Inc. Announces NYSE MKT Acceptance of its Plan of Compliance
Oragenics, Inc. Announces NYSE MKT Acceptance of its Plan of Compliance TAMPA, Fla. Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN the Company ) today announced that NYSE Regulation has accepted the Company s plan to regain compliance with the NYSE MKT e
Read more →OGENOragenics Announces Closing of $4.667 Million Private Placement Tampa, FL (
Oragenics Announces Closing of $4.667 Million Private Placement Tampa, FL (June 30, 2016) Oragenics, Inc. (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and probiotics for oral health in humans and pets, today announced the clos
Read more →OGENOragenics Announces Completion of Sale of Consumer Probiotic Business Tampa, FL (
Oragenics Announces Completion of Sale of Consumer Probiotic Business Tampa, FL (June 27, 2016) Oragenics, Inc. (NYSE MKT: OGEN.BC) (the Company ), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis
Read more →OGENOragenics Announces Entry into Definitive Agreement to Sell Consumer Probiotic Business Tampa, FL (
Oragenics Announces Entry into Definitive Agreement to Sell Consumer Probiotic Business Tampa, FL (June 23, 2016) Oragenics, Inc. (NYSE MKT: OGEN), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis
Read more →OGENOragenics Announces new President, Chief Executive Officer and Member of the Board of Directors For Immediate Release Tampa, FL (
Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors Tampa, FL (June 6, 2016) Oragenics, Inc. (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral
Read more →OGENOragenics, Inc. Announces Notification of Noncompliance with NYSE MKT Continued Listing Standards For Immediate Release TAMPA, FL
Oragenics, Inc. Announces Notification of Noncompliance with NYSE MKT Continued Listing Standards 13, 2016 Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN the Company ) today announced receipt of notification (the Deficiency Letter ) from the NYSE MKT LLC
Read more →OGENOragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study Lead Lantibiotic Clinical Candidate Selected from MU1140 Analog Pipeline For Immediate Release TAMPA, FL & GERMANTOWN, MD
Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study Lead Lantibiotic Clinical Candidate Selected from MU1140 Analog Pipeline GERMANTOWN, MD - July 28, 2015 - Oragenics, Inc. (NYSE MKT: OGEN) and Intrexon Corporation (NYSE:XON), a leader in synth
Read more →OGENOragenics Shareholders Re-elect Existing Board of Directors; Approve and Ratify other Proposals For Immediate Release TAMPA, FL
Oragenics Shareholders Re-elect Existing Board of Directors; Approve and Ratify other Proposals 2015 Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN) has announced today that, based on proxies submitted to the independent Inspector of Election for its 2015
Read more →OGENIntrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral Cavity Companies to Progress ActoBiotic TM AG013 for Treatment of Oral Mucositis Oragenics Now A Clinical Stage Company GE
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral Cavity Companies to Progress ActoBioticTM AG013 for Treatment of Oral Mucositis Oragenics Now A Clinical Stage Company GERMANTOWN, MD, and TAMPA, FL, June 10, 2015 Intrexon Corpo
Read more →OGENOragenics, Inc. to Explore Strategic Alternatives for its OTC Probiotic Products Business TAMPA, FL
Oragenics, Inc. to Explore Strategic Alternatives for its OTC Probiotic Products Business TAMPA, FL December 22, 2014 Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN) has announced today that its board of directors has authorized the exploration of strate
Read more →OGENOragenics, Inc. Announces Change in Management and Board of Directors For Immediate Release TAMPA, FL
Oragenics, Inc. Announces Change in Management and Board of Directors TAMPA, FL October 30, 2014 Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT OGEN) has announced that on October 30, 2014 , Dr. John Bonfiglio resigned as Chief Executive Officer, President an
Read more →OGENCertain statements made in this presentation include forward looking actions that Oragenics, Inc. ( Oragenics, or the Company ) anticipates based on certain assumptions. These statements are indicated by words such as ex
MBA from The Florida State University 30 years of management and pharmaceutical experience Prior CEO Argos Therapeutics, CEO Immune Response, CEO Peregrine Pharmaceuticals, COO Cypress Bio Senior Management positions at Allergan Pharmaceuticals and Baxter Healthcare MS and PhD in
Read more →OGENOragenics Announces Completion of Public Offering of Common Stock TAMPA, Fla. (
Oragenics Announces Completion of Public Offering of Common Stock TAMPA, Fla. (November 20, 2013) Oragenics, Inc. (NYSE MKT: OGEN) (the Company ) announced today that it has completed its previously announced underwritten public offering of 4,400,000 shares of common stock at a
Read more →OGENOragenics Prices Public Offering of Common Stock TAMPA, Fla. (
Oragenics Prices Public Offering of Common Stock TAMPA, Fla. (November 15, 2013) Oragenics, Inc. (NYSE MKT: OGEN) (the Company ) announced today that it has priced an underwritten public offering of 4,400,000 shares of its common stock at a public offering price of $2.50 per sh
Read more →OGENOragenics Announces Proposed Public Offering of Common Stock TAMPA
Oragenics Announces Proposed Public Offering of Common Stock TAMPA, November 14, 2013 Oragenics, Inc. (NYSE MKT: OGEN) today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration state
Read more →OGENOragenics Announces Breakthrough Antibiotic Analog Generation in Intrexon Collaboration Marks Significant Step Towards Production of Lantibiotics and Pipeline Expansion Engineers Genetically-Modified Host to generate Mut
Oragenics Announces Breakthrough Antibiotic Analog Generation in Intrexon Collaboration Marks Significant Step Towards Production of Lantibiotics and Pipeline Expansion Engineers Genetically-Modified Host to generate Mutacin 1140 Analog(s) TAMPA, FL (October 31, 2013) Oragenic
Read more →OGENOragenics and Intrexon to Develop Genetically Modified Probiotics New Exclusive Channel Collaboration focused on Probiotics for the Treatment of Oral Cavity, Throat, Sinus and Esophagus Diseases Intrexon Invests $3.9 Mil
Oragenics and Intrexon to Develop Genetically Modified Probiotics New Exclusive Channel Collaboration focused on Probiotics for the Treatment of Oral Cavity, Throat, Sinus and Esophagus Diseases Intrexon Invests $3.9 Million in Oragenics Common Stock Tampa, FL and Germantown,
Read more →OGENOragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project TAMPA, FL (
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project TAMPA, FL (August 26, 2013) Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic
Read more →OGENOragenics Announces Approval of Common Stock Listing on NYSE MKT TAMPA, Fla. (
Oragenics Announces Approval of Common Stock Listing on NYSE MKT TAMPA, Fla. (April 8, 2013) Oragenics, Inc. (OTCBB: OGEN) (the Company ) announced today that its common stock has been approved for listing on the NYSE Euronext s NYSE MKT. Trading is expected to commence on the
Read more →OGENOragenics Announces Completion of $13 Million Private Placement Financing and Conversion of $2.5 Million Secured Indebtedness TAMPA, Fla. (
Oragenics Announces Completion of $13 Million Private Placement Financing and Conversion of $2.5 Million Secured Indebtedness TAMPA, Fla. (August 2, 2012) Oragenics, Inc. (OTCBB:ORNI) (the Company ) announced that it has completed its previously announced private placement in c
Read more →OGENOragenics Announces $12.86 Million Private Placement Financing TAMPA, Fla. (
Oragenics Announces $12.86 Million Private Placement Financing TAMPA, Fla. (July 31, 2012) - Oragenics, Inc. (OTCBB:ORNI) (the Company ) announced today that it has entered into a definitive stock purchase agreement with accredited investors to raise $12,863,332 in a private pl
Read more →OGENOragenics and Intrexon Announce Worldwide Exclusive Collaboration for Lantibiotics For Immediate Release Tampa, FL, & Germantown, MD
Oragenics and Intrexon Announce Worldwide Exclusive Collaboration for Lantibiotics Tampa, FL, & Germantown, MD, June 6, 2012 Oragenics, Inc. (OTCBB: ORNI) (the Company ), a leader in the area of oral care probiotics and a developer of therapeutic products including novel antibi
Read more →OGENOragenics Announces the Completion of $2.5 Million of Secured Debt Funding and Exchange of $8.737 Million of Unsecured Debt for Common Stock TAMPA, Fla. (
Oragenics Announces the Completion of $2.5 Million of Secured Debt Funding and Exchange of $8.737 Million of Unsecured Debt for Common Stock TAMPA, Fla. (March 26, 2012) - Oragenics, Inc. (OTCBB:ORNI) (the Company ) announced that the Company entered into a new loan agreement
Read more →OGENOragenics, Inc. Announces Appointment of Michael Sullivan as Chief Financial Officer For Immediate Release Tampa, FL (
Oragenics, Inc. Announces Appointment of Michael Sullivan as Chief Financial Officer (February 2, 2012) Oragenics, Inc. (OTCBB: ORNI) www.oragenics.com a nutraceutical company focused on oral care probiotics for humans and companion pets (the Company ), announced the appointment
Read more →OGENOragenics Announces Fourth Amendment to Unsecured Revolving Line of Credit to Provide $500,000 of Additional Funding
Oragenics Announces Fourth Amendment to Unsecured Revolving Line of Credit to Provide $500,000 of TAMPA, Fla. December 14, 2011 Oragenics, Inc. (OTCQB:ORNI) (the Company ), announced on December 9, 2011, that the Company has entered into a Fourth Amendment (the Fourth Amendment
Read more →OGENOragenics Announces Retirement of Dr. Jeffrey Hillman For Immediate Release Tampa, FL (
Oragenics Announces Retirement of Dr. Jeffrey Hillman (October 14, 2011) Oragenics, Inc. (OTCBB: ORNI.OB www.oragenics.com), a biopharmaceutical company (the Company ), announced today that its founder and Chief Scientific Officer, Dr. Jeffrey Hillman, will retire from full tim
Read more →OGENOragenics Announces Third Amendment to Unsecured Revolving Line of Credit to Provide up to $2.0 MM of Additional Funding For Immediate Release: Tampa, FL (
Oragenics Announces Third Amendment to Unsecured Revolving Line of Credit to Provide up to $2.0 MM of Additional Funding For Immediate Release: Tampa, FL (June 30, 2011) - On June 29, 2011, Oragenics, Inc. (OTCBB: ORNI.D www.oragenics.com), a biopharmaceutical company (the Co
Read more →OGENOragenics Adds Independent Director, Dr. Alan Dunton, to its Board of Directors For Immediate Release Tampa, FL (
Oragenics Adds Independent Director, Dr. Alan Dunton, to its Board of Directors (April 4, 2011) Oragenics, Inc. (OTCBB: ORNI.D www.oragenics.com), a biopharmaceutical company, announced today that Dr. Alan Dunton formally joined the Company s Board of Directors on April 1, 2011
Read more →OGENOragenics, Inc. Announces Second Amendment to Unsecured Revolving Line of Credit to Provide up to $2.5 MM of Additional Funding For Immediate Release Tampa, FL (
Oragenics, Inc. Announces Second Amendment to Unsecured Revolving Line of Credit to Provide up to $2.5 MM of Additional Funding Tampa, FL (February 7, 2011) Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI, www.oragenics.com) has announced that on Friday, F
Read more →OGENOragenics, Inc. Launches EvoraPlus Oral Care Probiotics Into GNC Stores For Immediate Release Tampa, FL (
Oragenics, Inc. Launches EvoraPlus Oral Care Probiotics Into GNC Stores Tampa, FL (Sept. 7, 2010) Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI www.oragenics.com) announced today that its oral care probiotic EvoraPlus (www.evoraplus.com) is now expected
Read more →OGENOragenics Announces Entering into Agreement to provide $2.0MM Equity Financing, which Includes the Conversion of $1.0MM Unsecured Note into Equity and Additional $2.0MM Unsecured Revolving Line of Credit For Immediate Re
Announces Entering into Agreement to provide $2.0MM Equity which Includes the Conversion of $1.0MM Unsecured Note into Equity Additional $2.0MM Unsecured Revolving Line of Credit Tampa, FL (July 7, 2010) - On July 5, 2010, Oragenics, Inc. (the "Company") entered into a Common
Read more →OGENOragenics Adds Two New Independent Board Members Dr. Frederick W. Telling and Charles L. Pope Bring Invaluable Experience to the Oragenics Board of Directors For Immediate Release Tampa, FL (
Adds Two New Independent Board Members Frederick W. Telling and Charles L. Pope Bring Invaluable Experience to the Oragenics Board of Directors Tampa, FL (June 7, 2010) - Oragenics, Inc. (OTCBB: ORNI www.oragenics.com), a biopharmaceutical company, announced today that Dr.
Read more →OGENOragenics, Inc., and RICCI PHARMA Sign Agreement Expected to Provide EvoraPlus and EvoraKids to the United Nations, UNESCO, UNICEF, World Health Organization and The Food and Agriculture Organization Florida-Based Biotec
Inc., and RICCI PHARMA Sign Agreement Expected to Provide EvoraPlus and EvoraKids to the United Nations, UNESCO, UNICEF, World Health Organization and The Food and Agriculture Organization Biotechnology Innovator and Rome-Based Health Product Provider Bring Probiotic Oral Car
Read more →OGENOragenics, Inc. 4 th Quarter Update Oragenics is Scheduled to Sell Its Acclaimed Probiotic Oral Care Product EvoraPlus Through Some Of The Country's Biggest Mass Retailers during 2010 Oragenics Also Positions Company's P
is Scheduled to Sell Its Acclaimed Probiotic Oral Care Product EvoraPlus Through Some Of The Country's Biggest Mass Retailers Also Positions Company's Probiotic Technology For Domestic And International Licensing And Private Label Distribution Deals With Major Global Pharmaceu
Read more →OGENUnassociated Document FOR IMMEDIATE RELEASE ORAGENICS ANNOUNCES $5,000,000 IN NEW FINANCING, AND CHANGES IN ITS BOARD OF DIRECTORS AND MANAGEMENT ALACHUA, FLORIDA, USA - (
ANNOUNCES $5,000,000 NEW FINANCING, AND CHANGES ITS BOARD OF DIRECTORS AND MANAGEMENT USA - (June 30, 2009) - The Florida based biotechnology firm Oragenics, Inc., announces that it has closed an investment contract with the Koski Family Limited Partnership to provide new ca
Read more →OGENCORPORATE OVERVIEW JANUARY 2009 This presentation does not constitute an offering of any securities for sale or a solicitation of offers to purchase securities. The Company's securities may not be offered or sold absent
This presentation does not constitute an offering of any securities for sale or a solicitation of offers to purchase securities. The Company's securities may not be offered or sold under applicable securities laws or an exemption from registration. Any public offering of the s
Read more →OGENONI BioPharma Announces EvoraPlus Website Now Available to Consumers Commencement of Trading on Alternext Paris; Company to Delist from American Stock Exchange Company to be Available for Investor Questions Regarding Rec
BioPharma Announces EvoraPlus Website Now Available to Consumers of Trading on Alternext Paris; Company to Delist from American Stock to be Available for Investor Questions Regarding Recent Events through E-mail FLORIDA, USA - (BUSINESS WIRE) - Dec. 12, 2008 - Oragenics, Inc.
Read more →OGENONI BIOPHARMA ANNOUNCES ITS LISTING ON ALTERNEXT PARIS ONI BioPharma will be the first US company to list on Alternext Paris PARIS, France, and ALACHUA, Florida, USA (
BIOPHARMA ANNOUNCES ITS LISTING BioPharma will be the first US company list on Alternext Paris France, and ALACHUA, Florida, USA (December 10, 2008) - Oragenics, Inc. d/b/a ONI BioPharma Inc. (Alternext US1: "ONI"), an American biopharmaceutical company that has developed br
Read more →OGENONI BIOPHARMA ANNOUNCES PROPOSED RIGHTS OFFERING TO SHAREHOLDERS ALACHUA, FL (
RIGHTS OFFERING TO SHAREHOLDERS FL (December 5, 2008) - Oragenics, BioPharma Inc. (Alternext US1 : announced today that it intends to distribute, at no charge, to the holders its Common Stock transferable subscription rights entitling the holders to collectively subscribe fo
Read more →OGENONI BIOPHARMA INC. OFFERS INVESTOR UPDATE. TOPICS INCLUDE: (1) APPEAL OF AMERICAN STOCK EXCHANGE DELISTING DECISION, (2) OPERATIONAL UPDATE AND (3) ANNOUNCEMENT OF INVESTOR CONFERENCE CALL ALACHUA, FL (
BIOPHARMA INC. OFFERS INVESTOR UPDATE. TOPICS INCLUDE: (1) APPEAL OF AMERICAN STOCK EXCHANGE DELISTING DECISION, (2) OPERATIONAL UPDATE AND (3) ANNOUNCEMENT OF INVESTOR CONFERENCE CALL FL (October 31, 2008) - Oragenics, BioPharma Inc. (The ASE: "ONI") announced, that it recei
Read more →OGENONI BioPharma Appoints New Chief Operational Officer ALACHUA, FL (
ONI BioPharma Appoints New Chief Operational Officer ALACHUA, FL (July 1, 2008) ONI BioPharma Inc. (AMEX: ONI), a biopharmaceutical company, today announced that David B. Hirsch has been appointed to Chief Operating Officer and Chief Financial Officer to succeed Dorothy Delfino
Read more →OGENONI BioPharma Inc. Announces Closing on $2,600,000 in Equity Financing Friday June 13, 9:00 am ET ALACHUA, FL (MARKET WIRE)
ONI BioPharma Inc. Announces Closing on $2,600,000 in Equity Financing Friday June 13, 9:00 am ET ALACHUA, FL (MARKET WIRE) June 13, 2008 Oragenics Inc. (ONI BioPharma Inc.) (AMEX:ONI - News) today reported that it has closed on its previously announced equity financing of $2,
Read more →OGENONI BioPharma Inc. Announces Definitive Term Sheet for $2,600,000 in Equity Financing FOR IMMEDIATE RELEASE ALACHUA, FL (
ONI BioPharma Inc. Announces Definitive Term Sheet for $2,600,000 in Equity Financing ALACHUA, FL (June 2, 2008) Oragenics Inc. (ONI BioPharma Inc.) (AMEX: ONI ) today reported that it has entered into a definitive financing agreement providing for equity financing of $2,600,00
Read more →OGENOragenics, Inc. (ONI BioPharma Inc.) Receives Notification Letter from American Stock Exchange FOR IMMEDIATE RELEASE ALACHUA, FL (
Oragenics, Inc. (ONI BioPharma Inc.) Receives Notification Letter from American Stock Exchange ALACHUA, FL (May 16, 2008) Oragenics, Inc. (d/b/a ONI BioPharma Inc.) (AMEX: ONI ) today reported it had received notice from the American Stock Exchange ( AMEX ) advising the Company
Read more →OGENOragenics, Inc. Changes Name to ONI Biopharma Inc. FOR IMMEDIATE RELEASE ALACHUA, FL (May13, 2008) Oragenics, Inc. (AMEX:ONI) announced today that its Board of Directors approved the use of the Company s new name of ONI
Oragenics, Inc. Changes Name to ONI Biopharma Inc. ALACHUA, FL (May13, 2008) Oragenics, Inc. (AMEX:ONI) announced today that its Board of Directors approved the use of the Company s new name of ONI BioPharma Inc. The Company recently registered in the State of Florida to do bus
Read more →OGENOragenics Announces Test Marketing of Probiora3 Chewable Tablets FOR IMMEDIATE RELEASE ALACHUA, FL (
Oragenics Announces Test Marketing of Probiora3 Chewable Tablets ALACHUA, FL (May 9, 2008) Oragenics, Inc. (AMEX:ONI) announced today the test marketing of its oral probiotic product, Probiora3. The chewable tablets help to whiten teeth and improve breath though the use of a un
Read more →OGENDr. Marc Siegel and Kevin Sills Join Oragenics Board of Directors FOR IMMEDIATE RELEASE ALACHUA, FL (
Dr. Marc Siegel and Kevin Sills Join Oragenics Board of Directors ALACHUA, FL (April 28, 2008) Oragenics, Inc. (AMEX:ONI) announced today that Dr. Marc Siegel and Mr. Kevin Sills have been appointed to the Company s Board of Directors. Dr. Siegel is a leader in the discussion o
Read more →OGENOragenics, Inc. Announces the Early Exercise of Warrants FOR IMMEDIATE RELEASE ALACHUA, FL (
Oragenics, Inc. Announces the Early Exercise of Warrants ALACHUA, FL (March 3, 2008) Oragenics, Inc. (AMEX:ONI), a biotechnology company focused primarily on infectious diseases, announced today that a total of 3,386,364 warrants issued to investors who participated in the Augu
Read more →OGENOragenics Announces the Exercise of Warrants and a Management Change Alachua, FL (
Oragenics Announces the Exercise of Warrants and a Management Change Alachua, FL (February 12, 2008) Oragenics, Inc. (AMEX:ONI) announced today that seven shareholders who received warrants as part of their March 2006 investment in Oragenics have exercised stock warrants which
Read more →OGENOragenics Announces Issuing of Amended Warrants Alachua, FL (
Oragenics Announces Issuing of Amended Warrants Alachua, FL (January 29, 2008) Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced today a financing opportunity for its existing August 2007 warrant holders. The Board of Directors approved the reduction
Read more →OGENOragenics announces the Appointment of Two New Board Members Alachua, FL (
Oragenics announces the Appointment of Two New Board Members Alachua, FL (January 21, 2008) Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced today further expansion of the Board of Directors with two talented and experienced Board members, Derek Hennec
Read more →OGENOragenics announces retirement of its CEO, selects a new CEO and President, and appoints a new Board Member. Alachua, FL (
Oragenics announces retirement of its CEO, selects a new CEO and President, and appoints a new Board Member. Alachua, FL (January 2, 2008) Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced today several new developments in the leadership and direction o
Read more →OGENOragenics Appoints Dr. Ronald P. Evens to its Board of Directors FOR IMMEDIATE RELEASE ALACHUA, FL (
Oragenics Appoints Dr. Ronald P. Evens to its Board of Directors ALACHUA, FL (June 18, 2007) Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced today that Dr. Ronald Evens has been appointed to the Company s Board of Directors. Dr. Evens has a tremendous
Read more →Competitive Position
How OGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how OGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial